Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Yasutaka Ishii

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3545-8743; OpenAlex author ID A5091195999. Sources: OpenAlex.

Their work

Papers
21 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 4 papers · 2022: 2 papers · 2023: 6 papers · 2024: 1 paper · 2025: 1 paper · 2026: 5 papers

Papers 21

  1. Clinical outcomes and recurrence patterns in pancreatic ductal adenocarcinoma diagnosed at an early stage: insights from a multicenter cohort study in Japan. First author DOI 10.1007/s00535-025-02340-x↗
  2. Minichromosome maintenance 4 is associated with poor survival and stemness of patients with pancreatic cancer. Co-author DOI 10.1007/s00795-025-00438-y↗
  3. Comparative Study of Pathological and Imaging Findings in High-Grade Pancreatic Intraepithelial Neoplasia: A Multicenter Analysis by the Japan Study Group on E… Co-author DOI 10.1097/mpa.0000000000002710↗
  4. Prognostic Impact of the Combined Use of CA19-9 and DUPAN-2 in Initially Unresectable Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-026-20710-4↗
  5. Early detection of pancreatic ductal adenocarcinoma by single-molecule profiling of pancreatic enzyme activities Co-author DOI 10.64898/2026.06.05.730533↗
  6. Survival benefit of adjuvant therapy completion with early initiation for patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12898↗
  7. Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15221-z↗
  8. Surgical resection for liver recurrence after curative resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00423-023-03009-w↗
  9. Prognostic factor in patient with recurrent pancreatic adenocarcinoma. Co-author DOI 10.1007/s00423-023-03073-2↗
  10. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis. Co-author DOI 10.1007/s10147-023-02317-x↗
  11. Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutatio… Co-author DOI 10.1007/s12328-022-01741-2↗
  12. Diagnostic Ability and Safety of Repeated Pancreatic Juice Cytology Using an Endoscopic Nasopancreatic Drainage Catheter for Pancreatic Ductal Adenocarcinoma: … First author DOI 10.3390/diagnostics13162696↗
  13. Utility of Covered Self-Expanding Metal Stents for Biliary Drainage during Neoadjuvant Chemotherapy in Patients with Borderline Resectable Pancreatic Cancer. First author DOI 10.3390/jcm12196245↗
  14. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer. Co-author DOI 10.1007/s00423-021-02339-x↗
  15. Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2022.02.001↗
  16. The role of apparent diffusion coefficient value in the diagnosis of localized type 1 autoimmune pancreatitis: differentiation from pancreatic ductal adenocarc… First author DOI 10.1007/s00261-020-02907-7↗
  17. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.pan.2021.01.022↗
  18. Role of Endoscopic Ultrasonography and Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Pancreatic Cancer. Co-author DOI 10.3390/diagnostics11020238↗
  19. Clinical Analysis of Early-Stage Pancreatic Cancer and Proposal for a New Diagnostic Algorithm: A Multicenter Observational Study. Co-author DOI 10.3390/diagnostics11020287↗
  20. Preoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery. Co-author DOI 10.1155/2016/7968201↗
  21. [Hepatic artery pseudoaneurysm after endoscopic biliary stenting for pancreatic cancer]. Co-author PMID 24806237↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kenichiro Uemura · 12 shared papers, 2016–2026 · strength 2.05
  2. Tatsuaki Sumiyoshi · 8 shared papers, 2021–2026 · strength 1.49
  3. Kenjiro Okada · 8 shared papers, 2021–2026 · strength 1.49
  4. Shin’ya Takahashi · 8 shared papers, 2021–2026 · strength 1.47
  5. Juri Ikemoto · 9 shared papers, 2021–2026 · strength 1.45
  6. Yoshiaki Murakami · 8 shared papers, 2016–2026 · strength 1.36
  7. Shiro Oka · 5 shared papers, 2023–2026 · strength 1.17
  8. Tomofumi Tsuboi · 9 shared papers, 2016–2023 · strength 1.07
  9. Shinya Nakamura · 7 shared papers, 2021–2026 · strength 1.07
  10. Ryuta Shintakuya · 5 shared papers, 2023–2026 · strength 1.04
  11. Keiji Hanada · 5 shared papers, 2021–2026 · strength 0.93
  12. Hiroyuki Otsuka · 5 shared papers, 2021–2023 · strength 0.79
  13. Takumi Harada · 3 shared papers, 2024–2026 · strength 0.70
  14. Kenta Baba · 3 shared papers, 2023–2025 · strength 0.60
  15. Sho Tazuma · 2 shared papers, 2026 · strength 0.53
  16. Masaru Furukawa · 3 shared papers, 2022–2026 · strength 0.53
  17. Tomoyuki Minami · 4 shared papers, 2014–2026 · strength 0.53
  18. Masanobu Yukutake · 3 shared papers, 2021–2026 · strength 0.49
  19. Atsushi Yamaguchi · 3 shared papers, 2021–2026 · strength 0.49
  20. Kazuaki Chayama · 5 shared papers, 2014–2021 · strength 0.41
  21. Ryota Kawamura · 4 shared papers, 2016–2022 · strength 0.39
  22. Akinori Shimizu · 3 shared papers, 2016–2026 · strength 0.38
  23. Takeshi Sudo · 1 shared paper, 2026 · strength 0.27
  24. Shinji Mii · 1 shared paper, 2026 · strength 0.27
  25. Akira Ishikawa · 1 shared paper, 2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.